| Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia … JP McEvoy, JM Meyer, DC Goff, HA Nasrallah, SM Davis, L Sullivan, ... Schizophrenia research 80 (1), 19-32, 2005 | 1583 | 2005 |
| The emerging role of glutamate in the pathophysiology and treatment of schizophrenia DC Goff, JT Coyle American Journal of psychiatry 158 (9), 1367-1377, 2001 | 1201 | 2001 |
| Regionally localized thinning of the cerebral cortex in schizophrenia GR Kuperberg, MR Broome, PK McGuire, AS David, M Eddy, F Ozawa, ... Archives of general psychiatry 60 (9), 878-888, 2003 | 1133 | 2003 |
| Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study DC Henderson, E Cagliero, C Gray, RA Nasrallah, DL Hayden, ... American Journal of Psychiatry 157 (6), 975-981, 2000 | 1105 | 2000 |
| Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. DC Goff, DC Henderson, E Amico The American journal of psychiatry 149 (9), 1189-1194, 1992 | 825 | 1992 |
| Impaired recruitment of the hippocampus during conscious recollection in schizophrenia S Heckers, S Rauch, D Goff, C Savage, D Schacter, A Fischman, N Alpert Nature neuroscience 1 (4), 318-323, 1998 | 734 | 1998 |
| Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline HA Nasrallah, JM Meyer, DC Goff, JP McEvoy, SM Davis, TS Stroup, ... Schizophrenia research 86 (1-3), 15-22, 2006 | 728 | 2006 |
| A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls DC Goff, LM Sullivan, JP McEvoy, JM Meyer, HA Nasrallah, GL Daumit, ... Schizophrenia research 80 (1), 45-53, 2005 | 695 | 2005 |
| Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance DS Manoach, RL Gollub, ES Benson, MM Searl, DC Goff, E Halpern, ... Biological psychiatry 48 (2), 99-109, 2000 | 623 | 2000 |
| Cognitive therapy for psychosis in schizophrenia: an effect size analysis RA Gould, KT Mueser, E Bolton, V Mays, D Goff Focus 48 (1), 335-101, 2004 | 558 | 2004 |
| A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia RW Buchanan, M Davis, D Goff, MF Green, RSE Keefe, AC Leon, ... Schizophrenia bulletin 31 (1), 5-19, 2005 | 553 | 2005 |
| A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia DC Goff, G Tsai, J Levitt, E Amico, D Manoach, DA Schoenfeld, ... Archives of general psychiatry 56 (1), 21-27, 1999 | 535 | 1999 |
| Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia JT Coyle, G Tsai, D Goff Annals of the New York Academy of Sciences 1003 (1), 318-327, 2003 | 525 | 2003 |
| Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI DS Manoach, DZ Press, V Thangaraj, MM Searl, DC Goff, E Halpern, ... Biological psychiatry 45 (9), 1128-1137, 1999 | 506 | 1999 |
| Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis DC Henderson, E Cagliero, PM Copeland, CP Borba, AE Evins, ... Archives of general psychiatry 62 (1), 19-28, 2005 | 496 | 2005 |
| Reduced sleep spindles and spindle coherence in schizophrenia: mechanisms of impaired memory consolidation? EJ Wamsley, MA Tucker, AK Shinn, KE Ono, SK McKinley, AV Ely, ... Biological psychiatry 71 (2), 154-161, 2012 | 464 | 2012 |
| Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. DC Goff, C Cather, AE Evins, DC Henderson, O Freudenreich, ... Journal of Clinical Psychiatry 66 (2), 183-194, 2005 | 439 | 2005 |
| Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1 JM Meyer, VG Davis, DC Goff, JP McEvoy, HA Nasrallah, SM Davis, ... Schizophrenia research 101 (1-3), 273-286, 2008 | 390 | 2008 |
| Association of psychiatric disorders with mortality among patients with COVID-19 K Nemani, C Li, M Olfson, EM Blessing, N Razavian, J Chen, E Petkova, ... JAMA psychiatry 78 (4), 380-386, 2021 | 335 | 2021 |
| Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. DC Goff, G Tsai, DS Manoach, JT Coyle The American journal of psychiatry 152 (8), 1213-1215, 1995 | 330 | 1995 |
